Core Insights - TG Therapeutics presented data on BRIUMVI® (ublituximab-xiiy) at the ACTRIMS annual forum, focusing on its clinical applications and real-world study results [1][2]. Company Overview - TG Therapeutics is a biopharmaceutical company dedicated to developing treatments for B-cell diseases, with BRIUMVI approved for treating adult patients with relapsing forms of multiple sclerosis (RMS) [29]. Clinical Studies - The ENABLE study evaluates real-world infusion experiences of patients with RMS on BRIUMVI, showcasing the company's commitment to advancing clinical understanding [2]. - The ULTIMATE I & II trials are Phase 3 studies involving 1,094 patients across 10 countries, comparing BRIUMVI to teriflunomide over 96 weeks [4]. Product Information - BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, designed to enhance B-cell depletion efficiency through glycoengineering [5][6]. - It is indicated for various forms of RMS, including clinically isolated syndrome and active secondary progressive disease [7]. Safety and Efficacy Data - In clinical trials, BRIUMVI showed a 56% overall infection rate compared to 54% for teriflunomide, with serious infections at 5% versus 3% [10]. - Infusion reactions occurred in 48% of patients receiving BRIUMVI, with serious reactions in 0.6% [8]. Market Context - Approximately 1 million people in the U.S. are living with MS, with 85% initially diagnosed with relapsing-remitting MS [28].